Stay updated with breaking news from Structural Heart Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.There was also no difference between the edoxaban (Savaysa, Daiichi Sankyo) and DAPT groups in cerebral thromboembolism and neurological or neurocognitive function,
It's time again to check the pulse — of Florida health care policy and politics.
PASCAL device safe and linked to symptom improvement in severe tricuspid regurgitation
The ADAPT-TAVR trial showed a numerical reduction in leaflet thrombosis with edoxaban versus dual antiplatelet therapy, but no reduction in cerebral events or neurocognitive function
A roundup of important career moves and accomplishments among physicians.